MOLECULES 润色咨询

MOLECULES

出版年份：1996 年文章数：35193 投稿命中率： 开通期刊会员，数据随心看

出版周期：Monthly 自引率：10.0% 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=1189039, encodeId=69f91189039d4, content=效率很高，拒的很快hhh, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9995609270, createdName=ms2000001458439795, createdTime=Sat Jan 29 09:47:15 CST 2022, time=2022-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1095754, encodeId=02a91095e54ec, content=一般期刊要求几张图/几个表？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Mon Dec 27 14:52:50 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=861550, encodeId=597386155095, content=5.13 submit<br> 5.14 under review<br> 6.2 minor revision<br> 6.4 revsubmit<br> 6.7 accept<br> 为了赶速度的<br> 相信molecules太好了<br> 神速感谢 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e295414102, createdName=ms4512939187244456, createdTime=Sun Jun 07 16:00:02 CST 2020, time=2020-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073179, encodeId=efeb10e31797b, content=偏重的研究方向：药理;通路<br>经验分享：这个杂志收中国医院的文章吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Zv31D0ib4gZlmqicebT1WbImxiaAAk8R4v6PNw2d4K02GK3a4pic0vIoUuN0KzOAb0KnWhctoDLib35DuwAOYvZpGzw/132, createdBy=c79e5155605, createdName=孟杰宝贝, createdTime=Tue Nov 23 13:40:55 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967276, encodeId=a8db96e276eb, content=请问进去Molecules投稿，投完稿显示杂志是medicines呢？两者之间的关系是什么呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3eac5505252, createdName=李白儿, createdTime=Thu May 20 17:11:12 CST 2021, time=2021-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=963317, encodeId=df0b96331e59, content=悲催，催了稿好像怒了，三个审稿意见，一个没意见，一个小修，一个完全否定，结果就拒了，得跟佛似的供着捧着么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de0c5463702, createdName=ms3000001817756113, createdTime=Fri May 07 09:23:30 CST 2021, time=2021-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956966, encodeId=1b399569664c, content=审稿几周, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de0c5463702, createdName=ms3000001817756113, createdTime=Wed Apr 14 17:22:28 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585238, encodeId=e81e58523825, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：审稿神速 1.31投稿 2.10major revision 2.19修回 2.23接收 编辑态度也很好 总体难度不大 就是版面费略贵, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=214, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/25/05c70c080d84f6afec99dab1d7b5ec27.jpg, createdBy=3a8e5197884, createdName=spiritak_34827477, createdTime=Sun Feb 23 20:42:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=574422, encodeId=00085e4422f6, content=请问你用了多久呢？我现在投稿以后就是这个状态，已经过了好几天了<span class="quote">153OcDe3069(暂无昵称) 2017-10-31 发表::<br>请问大家一般pending review 状态多久进入下一阶段？？？大神们</span><span class="quote">153OcDe3069(暂无昵称) 2017-10-31 19:30:00 发表:<br>请问大家一般pending review 状态多久进入下一阶段？？？大神们</span>, beContent=153OcDe3069(暂无昵称) 2017-10-31 发表:: 请问大家一般pending review 状态多久进入下一阶段？？？大神们, objectType=tool_impact_factor, channel=null, level=null, likeNumber=199, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/07/05/1e2beef086b8985fc951521ecf156cfc.jpg, createdBy=ab6b5134614, createdName=桃之妖妖, createdTime=Mon Aug 05 00:00:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=943929, encodeId=faf394392963, content=审稿速度:1.0 | 投稿命中率:95.0<br>经验分享：投了一篇药物作用肿瘤的机制研究，隔天送审，两周后拒稿。有两个审稿人，一个建议重新投，另一个可能是大修。最终编辑拒稿。速度还是很快的，就是悲剧了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=deae5456594, createdName=ms8000000688345398, createdTime=Sat Feb 27 13:47:20 CST 2021, time=2021-02-27, status=1, ipAttribution=)]
    2022-01-29 ms2000001458439795

    效率很高，拒的很快hhh

    1

    展开1条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=1189039, encodeId=69f91189039d4, content=效率很高，拒的很快hhh, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9995609270, createdName=ms2000001458439795, createdTime=Sat Jan 29 09:47:15 CST 2022, time=2022-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1095754, encodeId=02a91095e54ec, content=一般期刊要求几张图/几个表？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Mon Dec 27 14:52:50 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=861550, encodeId=597386155095, content=5.13 submit<br> 5.14 under review<br> 6.2 minor revision<br> 6.4 revsubmit<br> 6.7 accept<br> 为了赶速度的<br> 相信molecules太好了<br> 神速感谢 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e295414102, createdName=ms4512939187244456, createdTime=Sun Jun 07 16:00:02 CST 2020, time=2020-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073179, encodeId=efeb10e31797b, content=偏重的研究方向：药理;通路<br>经验分享：这个杂志收中国医院的文章吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Zv31D0ib4gZlmqicebT1WbImxiaAAk8R4v6PNw2d4K02GK3a4pic0vIoUuN0KzOAb0KnWhctoDLib35DuwAOYvZpGzw/132, createdBy=c79e5155605, createdName=孟杰宝贝, createdTime=Tue Nov 23 13:40:55 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967276, encodeId=a8db96e276eb, content=请问进去Molecules投稿，投完稿显示杂志是medicines呢？两者之间的关系是什么呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3eac5505252, createdName=李白儿, createdTime=Thu May 20 17:11:12 CST 2021, time=2021-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=963317, encodeId=df0b96331e59, content=悲催，催了稿好像怒了，三个审稿意见，一个没意见，一个小修，一个完全否定，结果就拒了，得跟佛似的供着捧着么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de0c5463702, createdName=ms3000001817756113, createdTime=Fri May 07 09:23:30 CST 2021, time=2021-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956966, encodeId=1b399569664c, content=审稿几周, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de0c5463702, createdName=ms3000001817756113, createdTime=Wed Apr 14 17:22:28 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585238, encodeId=e81e58523825, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：审稿神速 1.31投稿 2.10major revision 2.19修回 2.23接收 编辑态度也很好 总体难度不大 就是版面费略贵, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=214, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/25/05c70c080d84f6afec99dab1d7b5ec27.jpg, createdBy=3a8e5197884, createdName=spiritak_34827477, createdTime=Sun Feb 23 20:42:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=574422, encodeId=00085e4422f6, content=请问你用了多久呢？我现在投稿以后就是这个状态，已经过了好几天了<span class="quote">153OcDe3069(暂无昵称) 2017-10-31 发表::<br>请问大家一般pending review 状态多久进入下一阶段？？？大神们</span><span class="quote">153OcDe3069(暂无昵称) 2017-10-31 19:30:00 发表:<br>请问大家一般pending review 状态多久进入下一阶段？？？大神们</span>, beContent=153OcDe3069(暂无昵称) 2017-10-31 发表:: 请问大家一般pending review 状态多久进入下一阶段？？？大神们, objectType=tool_impact_factor, channel=null, level=null, likeNumber=199, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/07/05/1e2beef086b8985fc951521ecf156cfc.jpg, createdBy=ab6b5134614, createdName=桃之妖妖, createdTime=Mon Aug 05 00:00:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=943929, encodeId=faf394392963, content=审稿速度:1.0 | 投稿命中率:95.0<br>经验分享：投了一篇药物作用肿瘤的机制研究，隔天送审，两周后拒稿。有两个审稿人，一个建议重新投，另一个可能是大修。最终编辑拒稿。速度还是很快的，就是悲剧了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=deae5456594, createdName=ms8000000688345398, createdTime=Sat Feb 27 13:47:20 CST 2021, time=2021-02-27, status=1, ipAttribution=)]
    2021-12-27 msSSSSSD

    一般期刊要求几张图/几个表？

    1

    展开1条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=1189039, encodeId=69f91189039d4, content=效率很高，拒的很快hhh, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9995609270, createdName=ms2000001458439795, createdTime=Sat Jan 29 09:47:15 CST 2022, time=2022-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1095754, encodeId=02a91095e54ec, content=一般期刊要求几张图/几个表？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Mon Dec 27 14:52:50 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=861550, encodeId=597386155095, content=5.13 submit<br> 5.14 under review<br> 6.2 minor revision<br> 6.4 revsubmit<br> 6.7 accept<br> 为了赶速度的<br> 相信molecules太好了<br> 神速感谢 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e295414102, createdName=ms4512939187244456, createdTime=Sun Jun 07 16:00:02 CST 2020, time=2020-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073179, encodeId=efeb10e31797b, content=偏重的研究方向：药理;通路<br>经验分享：这个杂志收中国医院的文章吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Zv31D0ib4gZlmqicebT1WbImxiaAAk8R4v6PNw2d4K02GK3a4pic0vIoUuN0KzOAb0KnWhctoDLib35DuwAOYvZpGzw/132, createdBy=c79e5155605, createdName=孟杰宝贝, createdTime=Tue Nov 23 13:40:55 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967276, encodeId=a8db96e276eb, content=请问进去Molecules投稿，投完稿显示杂志是medicines呢？两者之间的关系是什么呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3eac5505252, createdName=李白儿, createdTime=Thu May 20 17:11:12 CST 2021, time=2021-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=963317, encodeId=df0b96331e59, content=悲催，催了稿好像怒了，三个审稿意见，一个没意见，一个小修，一个完全否定，结果就拒了，得跟佛似的供着捧着么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de0c5463702, createdName=ms3000001817756113, createdTime=Fri May 07 09:23:30 CST 2021, time=2021-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956966, encodeId=1b399569664c, content=审稿几周, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de0c5463702, createdName=ms3000001817756113, createdTime=Wed Apr 14 17:22:28 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585238, encodeId=e81e58523825, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：审稿神速 1.31投稿 2.10major revision 2.19修回 2.23接收 编辑态度也很好 总体难度不大 就是版面费略贵, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=214, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/25/05c70c080d84f6afec99dab1d7b5ec27.jpg, createdBy=3a8e5197884, createdName=spiritak_34827477, createdTime=Sun Feb 23 20:42:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=574422, encodeId=00085e4422f6, content=请问你用了多久呢？我现在投稿以后就是这个状态，已经过了好几天了<span class="quote">153OcDe3069(暂无昵称) 2017-10-31 发表::<br>请问大家一般pending review 状态多久进入下一阶段？？？大神们</span><span class="quote">153OcDe3069(暂无昵称) 2017-10-31 19:30:00 发表:<br>请问大家一般pending review 状态多久进入下一阶段？？？大神们</span>, beContent=153OcDe3069(暂无昵称) 2017-10-31 发表:: 请问大家一般pending review 状态多久进入下一阶段？？？大神们, objectType=tool_impact_factor, channel=null, level=null, likeNumber=199, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/07/05/1e2beef086b8985fc951521ecf156cfc.jpg, createdBy=ab6b5134614, createdName=桃之妖妖, createdTime=Mon Aug 05 00:00:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=943929, encodeId=faf394392963, content=审稿速度:1.0 | 投稿命中率:95.0<br>经验分享：投了一篇药物作用肿瘤的机制研究，隔天送审，两周后拒稿。有两个审稿人，一个建议重新投，另一个可能是大修。最终编辑拒稿。速度还是很快的，就是悲剧了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=deae5456594, createdName=ms8000000688345398, createdTime=Sat Feb 27 13:47:20 CST 2021, time=2021-02-27, status=1, ipAttribution=)]
    2020-06-07 ms4512939187244456

    5.13 submit
    5.14 under review
    6.2 minor revision
    6.4 revsubmit
    6.7 accept
    为了赶速度的
    相信molecules太好了
    神速感谢

    3

    展开3条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=1189039, encodeId=69f91189039d4, content=效率很高，拒的很快hhh, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9995609270, createdName=ms2000001458439795, createdTime=Sat Jan 29 09:47:15 CST 2022, time=2022-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1095754, encodeId=02a91095e54ec, content=一般期刊要求几张图/几个表？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Mon Dec 27 14:52:50 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=861550, encodeId=597386155095, content=5.13 submit<br> 5.14 under review<br> 6.2 minor revision<br> 6.4 revsubmit<br> 6.7 accept<br> 为了赶速度的<br> 相信molecules太好了<br> 神速感谢 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e295414102, createdName=ms4512939187244456, createdTime=Sun Jun 07 16:00:02 CST 2020, time=2020-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073179, encodeId=efeb10e31797b, content=偏重的研究方向：药理;通路<br>经验分享：这个杂志收中国医院的文章吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Zv31D0ib4gZlmqicebT1WbImxiaAAk8R4v6PNw2d4K02GK3a4pic0vIoUuN0KzOAb0KnWhctoDLib35DuwAOYvZpGzw/132, createdBy=c79e5155605, createdName=孟杰宝贝, createdTime=Tue Nov 23 13:40:55 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967276, encodeId=a8db96e276eb, content=请问进去Molecules投稿，投完稿显示杂志是medicines呢？两者之间的关系是什么呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3eac5505252, createdName=李白儿, createdTime=Thu May 20 17:11:12 CST 2021, time=2021-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=963317, encodeId=df0b96331e59, content=悲催，催了稿好像怒了，三个审稿意见，一个没意见，一个小修，一个完全否定，结果就拒了，得跟佛似的供着捧着么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de0c5463702, createdName=ms3000001817756113, createdTime=Fri May 07 09:23:30 CST 2021, time=2021-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956966, encodeId=1b399569664c, content=审稿几周, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de0c5463702, createdName=ms3000001817756113, createdTime=Wed Apr 14 17:22:28 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585238, encodeId=e81e58523825, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：审稿神速 1.31投稿 2.10major revision 2.19修回 2.23接收 编辑态度也很好 总体难度不大 就是版面费略贵, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=214, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/25/05c70c080d84f6afec99dab1d7b5ec27.jpg, createdBy=3a8e5197884, createdName=spiritak_34827477, createdTime=Sun Feb 23 20:42:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=574422, encodeId=00085e4422f6, content=请问你用了多久呢？我现在投稿以后就是这个状态，已经过了好几天了<span class="quote">153OcDe3069(暂无昵称) 2017-10-31 发表::<br>请问大家一般pending review 状态多久进入下一阶段？？？大神们</span><span class="quote">153OcDe3069(暂无昵称) 2017-10-31 19:30:00 发表:<br>请问大家一般pending review 状态多久进入下一阶段？？？大神们</span>, beContent=153OcDe3069(暂无昵称) 2017-10-31 发表:: 请问大家一般pending review 状态多久进入下一阶段？？？大神们, objectType=tool_impact_factor, channel=null, level=null, likeNumber=199, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/07/05/1e2beef086b8985fc951521ecf156cfc.jpg, createdBy=ab6b5134614, createdName=桃之妖妖, createdTime=Mon Aug 05 00:00:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=943929, encodeId=faf394392963, content=审稿速度:1.0 | 投稿命中率:95.0<br>经验分享：投了一篇药物作用肿瘤的机制研究，隔天送审，两周后拒稿。有两个审稿人，一个建议重新投，另一个可能是大修。最终编辑拒稿。速度还是很快的，就是悲剧了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=deae5456594, createdName=ms8000000688345398, createdTime=Sat Feb 27 13:47:20 CST 2021, time=2021-02-27, status=1, ipAttribution=)]
    2021-11-23 孟杰宝贝

    偏重的研究方向：药理;通路
    经验分享：这个杂志收中国医院的文章吗

    1

    展开1条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=1189039, encodeId=69f91189039d4, content=效率很高，拒的很快hhh, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9995609270, createdName=ms2000001458439795, createdTime=Sat Jan 29 09:47:15 CST 2022, time=2022-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1095754, encodeId=02a91095e54ec, content=一般期刊要求几张图/几个表？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Mon Dec 27 14:52:50 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=861550, encodeId=597386155095, content=5.13 submit<br> 5.14 under review<br> 6.2 minor revision<br> 6.4 revsubmit<br> 6.7 accept<br> 为了赶速度的<br> 相信molecules太好了<br> 神速感谢 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e295414102, createdName=ms4512939187244456, createdTime=Sun Jun 07 16:00:02 CST 2020, time=2020-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073179, encodeId=efeb10e31797b, content=偏重的研究方向：药理;通路<br>经验分享：这个杂志收中国医院的文章吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Zv31D0ib4gZlmqicebT1WbImxiaAAk8R4v6PNw2d4K02GK3a4pic0vIoUuN0KzOAb0KnWhctoDLib35DuwAOYvZpGzw/132, createdBy=c79e5155605, createdName=孟杰宝贝, createdTime=Tue Nov 23 13:40:55 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967276, encodeId=a8db96e276eb, content=请问进去Molecules投稿，投完稿显示杂志是medicines呢？两者之间的关系是什么呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3eac5505252, createdName=李白儿, createdTime=Thu May 20 17:11:12 CST 2021, time=2021-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=963317, encodeId=df0b96331e59, content=悲催，催了稿好像怒了，三个审稿意见，一个没意见，一个小修，一个完全否定，结果就拒了，得跟佛似的供着捧着么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de0c5463702, createdName=ms3000001817756113, createdTime=Fri May 07 09:23:30 CST 2021, time=2021-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956966, encodeId=1b399569664c, content=审稿几周, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de0c5463702, createdName=ms3000001817756113, createdTime=Wed Apr 14 17:22:28 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585238, encodeId=e81e58523825, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：审稿神速 1.31投稿 2.10major revision 2.19修回 2.23接收 编辑态度也很好 总体难度不大 就是版面费略贵, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=214, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/25/05c70c080d84f6afec99dab1d7b5ec27.jpg, createdBy=3a8e5197884, createdName=spiritak_34827477, createdTime=Sun Feb 23 20:42:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=574422, encodeId=00085e4422f6, content=请问你用了多久呢？我现在投稿以后就是这个状态，已经过了好几天了<span class="quote">153OcDe3069(暂无昵称) 2017-10-31 发表::<br>请问大家一般pending review 状态多久进入下一阶段？？？大神们</span><span class="quote">153OcDe3069(暂无昵称) 2017-10-31 19:30:00 发表:<br>请问大家一般pending review 状态多久进入下一阶段？？？大神们</span>, beContent=153OcDe3069(暂无昵称) 2017-10-31 发表:: 请问大家一般pending review 状态多久进入下一阶段？？？大神们, objectType=tool_impact_factor, channel=null, level=null, likeNumber=199, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/07/05/1e2beef086b8985fc951521ecf156cfc.jpg, createdBy=ab6b5134614, createdName=桃之妖妖, createdTime=Mon Aug 05 00:00:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=943929, encodeId=faf394392963, content=审稿速度:1.0 | 投稿命中率:95.0<br>经验分享：投了一篇药物作用肿瘤的机制研究，隔天送审，两周后拒稿。有两个审稿人，一个建议重新投，另一个可能是大修。最终编辑拒稿。速度还是很快的，就是悲剧了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=deae5456594, createdName=ms8000000688345398, createdTime=Sat Feb 27 13:47:20 CST 2021, time=2021-02-27, status=1, ipAttribution=)]
    2021-05-20 李白儿

    请问进去Molecules投稿，投完稿显示杂志是medicines呢？两者之间的关系是什么呢？

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1189039, encodeId=69f91189039d4, content=效率很高，拒的很快hhh, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9995609270, createdName=ms2000001458439795, createdTime=Sat Jan 29 09:47:15 CST 2022, time=2022-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1095754, encodeId=02a91095e54ec, content=一般期刊要求几张图/几个表？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Mon Dec 27 14:52:50 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=861550, encodeId=597386155095, content=5.13 submit<br> 5.14 under review<br> 6.2 minor revision<br> 6.4 revsubmit<br> 6.7 accept<br> 为了赶速度的<br> 相信molecules太好了<br> 神速感谢 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e295414102, createdName=ms4512939187244456, createdTime=Sun Jun 07 16:00:02 CST 2020, time=2020-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073179, encodeId=efeb10e31797b, content=偏重的研究方向：药理;通路<br>经验分享：这个杂志收中国医院的文章吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Zv31D0ib4gZlmqicebT1WbImxiaAAk8R4v6PNw2d4K02GK3a4pic0vIoUuN0KzOAb0KnWhctoDLib35DuwAOYvZpGzw/132, createdBy=c79e5155605, createdName=孟杰宝贝, createdTime=Tue Nov 23 13:40:55 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967276, encodeId=a8db96e276eb, content=请问进去Molecules投稿，投完稿显示杂志是medicines呢？两者之间的关系是什么呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3eac5505252, createdName=李白儿, createdTime=Thu May 20 17:11:12 CST 2021, time=2021-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=963317, encodeId=df0b96331e59, content=悲催，催了稿好像怒了，三个审稿意见，一个没意见，一个小修，一个完全否定，结果就拒了，得跟佛似的供着捧着么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de0c5463702, createdName=ms3000001817756113, createdTime=Fri May 07 09:23:30 CST 2021, time=2021-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956966, encodeId=1b399569664c, content=审稿几周, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de0c5463702, createdName=ms3000001817756113, createdTime=Wed Apr 14 17:22:28 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585238, encodeId=e81e58523825, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：审稿神速 1.31投稿 2.10major revision 2.19修回 2.23接收 编辑态度也很好 总体难度不大 就是版面费略贵, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=214, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/25/05c70c080d84f6afec99dab1d7b5ec27.jpg, createdBy=3a8e5197884, createdName=spiritak_34827477, createdTime=Sun Feb 23 20:42:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=574422, encodeId=00085e4422f6, content=请问你用了多久呢？我现在投稿以后就是这个状态，已经过了好几天了<span class="quote">153OcDe3069(暂无昵称) 2017-10-31 发表::<br>请问大家一般pending review 状态多久进入下一阶段？？？大神们</span><span class="quote">153OcDe3069(暂无昵称) 2017-10-31 19:30:00 发表:<br>请问大家一般pending review 状态多久进入下一阶段？？？大神们</span>, beContent=153OcDe3069(暂无昵称) 2017-10-31 发表:: 请问大家一般pending review 状态多久进入下一阶段？？？大神们, objectType=tool_impact_factor, channel=null, level=null, likeNumber=199, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/07/05/1e2beef086b8985fc951521ecf156cfc.jpg, createdBy=ab6b5134614, createdName=桃之妖妖, createdTime=Mon Aug 05 00:00:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=943929, encodeId=faf394392963, content=审稿速度:1.0 | 投稿命中率:95.0<br>经验分享：投了一篇药物作用肿瘤的机制研究，隔天送审，两周后拒稿。有两个审稿人，一个建议重新投，另一个可能是大修。最终编辑拒稿。速度还是很快的，就是悲剧了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=deae5456594, createdName=ms8000000688345398, createdTime=Sat Feb 27 13:47:20 CST 2021, time=2021-02-27, status=1, ipAttribution=)]
    2021-05-07 ms3000001817756113

    悲催，催了稿好像怒了，三个审稿意见，一个没意见，一个小修，一个完全否定，结果就拒了，得跟佛似的供着捧着么

    1

    展开1条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=1189039, encodeId=69f91189039d4, content=效率很高，拒的很快hhh, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9995609270, createdName=ms2000001458439795, createdTime=Sat Jan 29 09:47:15 CST 2022, time=2022-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1095754, encodeId=02a91095e54ec, content=一般期刊要求几张图/几个表？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Mon Dec 27 14:52:50 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=861550, encodeId=597386155095, content=5.13 submit<br> 5.14 under review<br> 6.2 minor revision<br> 6.4 revsubmit<br> 6.7 accept<br> 为了赶速度的<br> 相信molecules太好了<br> 神速感谢 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e295414102, createdName=ms4512939187244456, createdTime=Sun Jun 07 16:00:02 CST 2020, time=2020-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073179, encodeId=efeb10e31797b, content=偏重的研究方向：药理;通路<br>经验分享：这个杂志收中国医院的文章吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Zv31D0ib4gZlmqicebT1WbImxiaAAk8R4v6PNw2d4K02GK3a4pic0vIoUuN0KzOAb0KnWhctoDLib35DuwAOYvZpGzw/132, createdBy=c79e5155605, createdName=孟杰宝贝, createdTime=Tue Nov 23 13:40:55 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967276, encodeId=a8db96e276eb, content=请问进去Molecules投稿，投完稿显示杂志是medicines呢？两者之间的关系是什么呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3eac5505252, createdName=李白儿, createdTime=Thu May 20 17:11:12 CST 2021, time=2021-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=963317, encodeId=df0b96331e59, content=悲催，催了稿好像怒了，三个审稿意见，一个没意见，一个小修，一个完全否定，结果就拒了，得跟佛似的供着捧着么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de0c5463702, createdName=ms3000001817756113, createdTime=Fri May 07 09:23:30 CST 2021, time=2021-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956966, encodeId=1b399569664c, content=审稿几周, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de0c5463702, createdName=ms3000001817756113, createdTime=Wed Apr 14 17:22:28 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585238, encodeId=e81e58523825, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：审稿神速 1.31投稿 2.10major revision 2.19修回 2.23接收 编辑态度也很好 总体难度不大 就是版面费略贵, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=214, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/25/05c70c080d84f6afec99dab1d7b5ec27.jpg, createdBy=3a8e5197884, createdName=spiritak_34827477, createdTime=Sun Feb 23 20:42:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=574422, encodeId=00085e4422f6, content=请问你用了多久呢？我现在投稿以后就是这个状态，已经过了好几天了<span class="quote">153OcDe3069(暂无昵称) 2017-10-31 发表::<br>请问大家一般pending review 状态多久进入下一阶段？？？大神们</span><span class="quote">153OcDe3069(暂无昵称) 2017-10-31 19:30:00 发表:<br>请问大家一般pending review 状态多久进入下一阶段？？？大神们</span>, beContent=153OcDe3069(暂无昵称) 2017-10-31 发表:: 请问大家一般pending review 状态多久进入下一阶段？？？大神们, objectType=tool_impact_factor, channel=null, level=null, likeNumber=199, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/07/05/1e2beef086b8985fc951521ecf156cfc.jpg, createdBy=ab6b5134614, createdName=桃之妖妖, createdTime=Mon Aug 05 00:00:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=943929, encodeId=faf394392963, content=审稿速度:1.0 | 投稿命中率:95.0<br>经验分享：投了一篇药物作用肿瘤的机制研究，隔天送审，两周后拒稿。有两个审稿人，一个建议重新投，另一个可能是大修。最终编辑拒稿。速度还是很快的，就是悲剧了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=deae5456594, createdName=ms8000000688345398, createdTime=Sat Feb 27 13:47:20 CST 2021, time=2021-02-27, status=1, ipAttribution=)]
    2021-04-14 ms3000001817756113

    审稿几周

    2

    展开2条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=1189039, encodeId=69f91189039d4, content=效率很高，拒的很快hhh, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9995609270, createdName=ms2000001458439795, createdTime=Sat Jan 29 09:47:15 CST 2022, time=2022-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1095754, encodeId=02a91095e54ec, content=一般期刊要求几张图/几个表？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Mon Dec 27 14:52:50 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=861550, encodeId=597386155095, content=5.13 submit<br> 5.14 under review<br> 6.2 minor revision<br> 6.4 revsubmit<br> 6.7 accept<br> 为了赶速度的<br> 相信molecules太好了<br> 神速感谢 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e295414102, createdName=ms4512939187244456, createdTime=Sun Jun 07 16:00:02 CST 2020, time=2020-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073179, encodeId=efeb10e31797b, content=偏重的研究方向：药理;通路<br>经验分享：这个杂志收中国医院的文章吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Zv31D0ib4gZlmqicebT1WbImxiaAAk8R4v6PNw2d4K02GK3a4pic0vIoUuN0KzOAb0KnWhctoDLib35DuwAOYvZpGzw/132, createdBy=c79e5155605, createdName=孟杰宝贝, createdTime=Tue Nov 23 13:40:55 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967276, encodeId=a8db96e276eb, content=请问进去Molecules投稿，投完稿显示杂志是medicines呢？两者之间的关系是什么呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3eac5505252, createdName=李白儿, createdTime=Thu May 20 17:11:12 CST 2021, time=2021-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=963317, encodeId=df0b96331e59, content=悲催，催了稿好像怒了，三个审稿意见，一个没意见，一个小修，一个完全否定，结果就拒了，得跟佛似的供着捧着么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de0c5463702, createdName=ms3000001817756113, createdTime=Fri May 07 09:23:30 CST 2021, time=2021-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956966, encodeId=1b399569664c, content=审稿几周, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de0c5463702, createdName=ms3000001817756113, createdTime=Wed Apr 14 17:22:28 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585238, encodeId=e81e58523825, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：审稿神速 1.31投稿 2.10major revision 2.19修回 2.23接收 编辑态度也很好 总体难度不大 就是版面费略贵, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=214, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/25/05c70c080d84f6afec99dab1d7b5ec27.jpg, createdBy=3a8e5197884, createdName=spiritak_34827477, createdTime=Sun Feb 23 20:42:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=574422, encodeId=00085e4422f6, content=请问你用了多久呢？我现在投稿以后就是这个状态，已经过了好几天了<span class="quote">153OcDe3069(暂无昵称) 2017-10-31 发表::<br>请问大家一般pending review 状态多久进入下一阶段？？？大神们</span><span class="quote">153OcDe3069(暂无昵称) 2017-10-31 19:30:00 发表:<br>请问大家一般pending review 状态多久进入下一阶段？？？大神们</span>, beContent=153OcDe3069(暂无昵称) 2017-10-31 发表:: 请问大家一般pending review 状态多久进入下一阶段？？？大神们, objectType=tool_impact_factor, channel=null, level=null, likeNumber=199, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/07/05/1e2beef086b8985fc951521ecf156cfc.jpg, createdBy=ab6b5134614, createdName=桃之妖妖, createdTime=Mon Aug 05 00:00:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=943929, encodeId=faf394392963, content=审稿速度:1.0 | 投稿命中率:95.0<br>经验分享：投了一篇药物作用肿瘤的机制研究，隔天送审，两周后拒稿。有两个审稿人，一个建议重新投，另一个可能是大修。最终编辑拒稿。速度还是很快的，就是悲剧了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=deae5456594, createdName=ms8000000688345398, createdTime=Sat Feb 27 13:47:20 CST 2021, time=2021-02-27, status=1, ipAttribution=)]
    2020-02-23 spiritak_34827477

    审稿速度:1.0 | 投稿命中率:50.0
    经验分享：审稿神速 1.31投稿 2.10major revision 2.19修回 2.23接收 编辑态度也很好 总体难度不大 就是版面费略贵

    5

    展开5条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=1189039, encodeId=69f91189039d4, content=效率很高，拒的很快hhh, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9995609270, createdName=ms2000001458439795, createdTime=Sat Jan 29 09:47:15 CST 2022, time=2022-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1095754, encodeId=02a91095e54ec, content=一般期刊要求几张图/几个表？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Mon Dec 27 14:52:50 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=861550, encodeId=597386155095, content=5.13 submit<br> 5.14 under review<br> 6.2 minor revision<br> 6.4 revsubmit<br> 6.7 accept<br> 为了赶速度的<br> 相信molecules太好了<br> 神速感谢 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e295414102, createdName=ms4512939187244456, createdTime=Sun Jun 07 16:00:02 CST 2020, time=2020-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073179, encodeId=efeb10e31797b, content=偏重的研究方向：药理;通路<br>经验分享：这个杂志收中国医院的文章吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Zv31D0ib4gZlmqicebT1WbImxiaAAk8R4v6PNw2d4K02GK3a4pic0vIoUuN0KzOAb0KnWhctoDLib35DuwAOYvZpGzw/132, createdBy=c79e5155605, createdName=孟杰宝贝, createdTime=Tue Nov 23 13:40:55 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967276, encodeId=a8db96e276eb, content=请问进去Molecules投稿，投完稿显示杂志是medicines呢？两者之间的关系是什么呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3eac5505252, createdName=李白儿, createdTime=Thu May 20 17:11:12 CST 2021, time=2021-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=963317, encodeId=df0b96331e59, content=悲催，催了稿好像怒了，三个审稿意见，一个没意见，一个小修，一个完全否定，结果就拒了，得跟佛似的供着捧着么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de0c5463702, createdName=ms3000001817756113, createdTime=Fri May 07 09:23:30 CST 2021, time=2021-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956966, encodeId=1b399569664c, content=审稿几周, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de0c5463702, createdName=ms3000001817756113, createdTime=Wed Apr 14 17:22:28 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585238, encodeId=e81e58523825, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：审稿神速 1.31投稿 2.10major revision 2.19修回 2.23接收 编辑态度也很好 总体难度不大 就是版面费略贵, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=214, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/25/05c70c080d84f6afec99dab1d7b5ec27.jpg, createdBy=3a8e5197884, createdName=spiritak_34827477, createdTime=Sun Feb 23 20:42:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=574422, encodeId=00085e4422f6, content=请问你用了多久呢？我现在投稿以后就是这个状态，已经过了好几天了<span class="quote">153OcDe3069(暂无昵称) 2017-10-31 发表::<br>请问大家一般pending review 状态多久进入下一阶段？？？大神们</span><span class="quote">153OcDe3069(暂无昵称) 2017-10-31 19:30:00 发表:<br>请问大家一般pending review 状态多久进入下一阶段？？？大神们</span>, beContent=153OcDe3069(暂无昵称) 2017-10-31 发表:: 请问大家一般pending review 状态多久进入下一阶段？？？大神们, objectType=tool_impact_factor, channel=null, level=null, likeNumber=199, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/07/05/1e2beef086b8985fc951521ecf156cfc.jpg, createdBy=ab6b5134614, createdName=桃之妖妖, createdTime=Mon Aug 05 00:00:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=943929, encodeId=faf394392963, content=审稿速度:1.0 | 投稿命中率:95.0<br>经验分享：投了一篇药物作用肿瘤的机制研究，隔天送审，两周后拒稿。有两个审稿人，一个建议重新投，另一个可能是大修。最终编辑拒稿。速度还是很快的，就是悲剧了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=deae5456594, createdName=ms8000000688345398, createdTime=Sat Feb 27 13:47:20 CST 2021, time=2021-02-27, status=1, ipAttribution=)]
    2019-08-05 桃之妖妖

    请问你用了多久呢？我现在投稿以后就是这个状态，已经过了好几天了153OcDe3069(暂无昵称) 2017-10-31 发表::
    请问大家一般pending review 状态多久进入下一阶段？？？大神们    153OcDe3069(暂无昵称) 2017-10-31 19:30:00 发表:
    请问大家一般pending review 状态多久进入下一阶段？？？大神们

    153OcDe3069(暂无昵称) 2017-10-31 发表:: 请问大家一般pending review 状态多久进入下一阶段？？？大神们

    5

    展开5条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=1189039, encodeId=69f91189039d4, content=效率很高，拒的很快hhh, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9995609270, createdName=ms2000001458439795, createdTime=Sat Jan 29 09:47:15 CST 2022, time=2022-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1095754, encodeId=02a91095e54ec, content=一般期刊要求几张图/几个表？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Mon Dec 27 14:52:50 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=861550, encodeId=597386155095, content=5.13 submit<br> 5.14 under review<br> 6.2 minor revision<br> 6.4 revsubmit<br> 6.7 accept<br> 为了赶速度的<br> 相信molecules太好了<br> 神速感谢 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e295414102, createdName=ms4512939187244456, createdTime=Sun Jun 07 16:00:02 CST 2020, time=2020-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073179, encodeId=efeb10e31797b, content=偏重的研究方向：药理;通路<br>经验分享：这个杂志收中国医院的文章吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Zv31D0ib4gZlmqicebT1WbImxiaAAk8R4v6PNw2d4K02GK3a4pic0vIoUuN0KzOAb0KnWhctoDLib35DuwAOYvZpGzw/132, createdBy=c79e5155605, createdName=孟杰宝贝, createdTime=Tue Nov 23 13:40:55 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967276, encodeId=a8db96e276eb, content=请问进去Molecules投稿，投完稿显示杂志是medicines呢？两者之间的关系是什么呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3eac5505252, createdName=李白儿, createdTime=Thu May 20 17:11:12 CST 2021, time=2021-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=963317, encodeId=df0b96331e59, content=悲催，催了稿好像怒了，三个审稿意见，一个没意见，一个小修，一个完全否定，结果就拒了，得跟佛似的供着捧着么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de0c5463702, createdName=ms3000001817756113, createdTime=Fri May 07 09:23:30 CST 2021, time=2021-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956966, encodeId=1b399569664c, content=审稿几周, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de0c5463702, createdName=ms3000001817756113, createdTime=Wed Apr 14 17:22:28 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585238, encodeId=e81e58523825, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：审稿神速 1.31投稿 2.10major revision 2.19修回 2.23接收 编辑态度也很好 总体难度不大 就是版面费略贵, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=214, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/25/05c70c080d84f6afec99dab1d7b5ec27.jpg, createdBy=3a8e5197884, createdName=spiritak_34827477, createdTime=Sun Feb 23 20:42:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=574422, encodeId=00085e4422f6, content=请问你用了多久呢？我现在投稿以后就是这个状态，已经过了好几天了<span class="quote">153OcDe3069(暂无昵称) 2017-10-31 发表::<br>请问大家一般pending review 状态多久进入下一阶段？？？大神们</span><span class="quote">153OcDe3069(暂无昵称) 2017-10-31 19:30:00 发表:<br>请问大家一般pending review 状态多久进入下一阶段？？？大神们</span>, beContent=153OcDe3069(暂无昵称) 2017-10-31 发表:: 请问大家一般pending review 状态多久进入下一阶段？？？大神们, objectType=tool_impact_factor, channel=null, level=null, likeNumber=199, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/07/05/1e2beef086b8985fc951521ecf156cfc.jpg, createdBy=ab6b5134614, createdName=桃之妖妖, createdTime=Mon Aug 05 00:00:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=943929, encodeId=faf394392963, content=审稿速度:1.0 | 投稿命中率:95.0<br>经验分享：投了一篇药物作用肿瘤的机制研究，隔天送审，两周后拒稿。有两个审稿人，一个建议重新投，另一个可能是大修。最终编辑拒稿。速度还是很快的，就是悲剧了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=deae5456594, createdName=ms8000000688345398, createdTime=Sat Feb 27 13:47:20 CST 2021, time=2021-02-27, status=1, ipAttribution=)]
    2021-02-27 ms8000000688345398

    审稿速度:1.0 | 投稿命中率:95.0
    经验分享：投了一篇药物作用肿瘤的机制研究，隔天送审，两周后拒稿。有两个审稿人，一个建议重新投，另一个可能是大修。最终编辑拒稿。速度还是很快的，就是悲剧了。

    1

    展开1条回复
共317条页码: 3/32页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分